Minerva Neurosciences (NERV) Non-Current Debt (2015 - 2017)
Minerva Neurosciences posted quarterly Non-Current Debt of $1.3 million for Q2 2017, down 78.69% year-on-year from $6.2 million in Q2 2016, and down 48.99% on a QoQ basis from $2.6 million in Q1 2017.
Minerva Neurosciences (NERV) has 3 years of Non-Current Debt data on file, last reported at $1.3 million in Q2 2017.
- For the quarter ending Q2 2017, Non-Current Debt fell 78.69% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2017 stood at $1.3 million (down 78.69% YoY), and the FY2016 full-year result was $3.8 million, down 54.83% from the prior year.
- Non-Current Debt for Q2 2017 stood at $1.3 million, down from $2.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $9.6 million in Q3 2015 and bottomed at $1.3 million in Q2 2017.
- The 3-year median for Non-Current Debt is $6.8 million (2016), against an average of $6.3 million.
- The widest annual swing landed in 2016, when Non-Current Debt fell 22.74%; it then sank 78.69% in 2017.
- A 3-year view of Non-Current Debt shows it stood at $8.5 million in 2015, then plunged by 54.83% to $3.8 million in 2016, then tumbled by 65.47% to $1.3 million in 2017.
- The last three Non-Current Debt figures came in at $1.3 million (Q2 2017), $2.6 million (Q1 2017), and $3.8 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 1.33 Mn |
| Jun 30, 2017 | 1.33 Mn |
| Mar 31, 2017 | 2.60 Mn |
| Mar 31, 2017 | 2.60 Mn |
| Dec 31, 2016 | 3.84 Mn |
| Dec 31, 2016 | 3.84 Mn |
| Sep 30, 2016 | 5.05 Mn |
| Sep 30, 2016 | 5.05 Mn |
| Jun 30, 2016 | 6.23 Mn |
| Jun 30, 2016 | 6.23 Mn |
| Mar 31, 2016 | 7.38 Mn |
| Mar 31, 2016 | 7.38 Mn |
| Dec 31, 2015 | 8.50 Mn |
| Dec 31, 2015 | 8.50 Mn |
| Sep 30, 2015 | 9.61 Mn |
| Sep 30, 2015 | 9.61 Mn |
| Jun 30, 2015 | 8.70 Mn |
| Jun 30, 2015 | 8.70 Mn |
| Mar 31, 2015 | 9.55 Mn |
| Mar 31, 2015 | 9.55 Mn |